細(xì)胞程序性死亡蛋白1配體2(PDL2)活性蛋白
Active Programmed Cell Death Protein 1 Ligand 2 (PDL2)
CD273; B7DC; Btdc; PD-L2; PDCD1-L2; PDCD1LG2
- 編號(hào)APA789Hu61
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)6.7
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1128 ¥ 2820 ¥ 5640 ¥ 16920 ¥ 42300
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
活性實(shí)驗(yàn)
Programmed Cell Death 1 Ligand 2 (also known as PD-L2, B7-DC) is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance. Mature human PD-L2 consists of a 201 amino acid (aa) extracellular domain (ECD) with one V-like and one C-like Ig domain, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain. PD-L2 has also been designated as CD273 (cluster of differentiation 273). PD-L2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response. PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1). A binding ELISA assay was conducted to detect the interaction of recombinant human PD-L2 and recombinant human PD-1. Briefly, PD-L2 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100μl were then transferred to PD-1-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PD-L2 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450/630nm immediately. The binding activity of PD-L2 and PD-1 was shown in Figure 1, the ED50 for this effect is 144 ng/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA789Hu61 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA789Hu61 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA789Hu01 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA789Hu62 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA789Hu01 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)多克隆抗體 | WB; IHC; ICC; IP. |
FAA789Hu01 | 抗細(xì)胞程序性死亡蛋白1配體2(PDL2)多克隆抗體 | Flow cytometry. |
MAA789Hu27 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA789Hu21 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA789Hu22 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA789Hu23 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA789Hu24 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA789Hu25 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA789Hu29 | 細(xì)胞程序性死亡蛋白1配體2(PDL2)單克隆抗體 | WB; IHC; ICC; IP. |
SEA789Hu | 細(xì)胞程序性死亡蛋白1配體2(PDL2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA789Hu | 細(xì)胞程序性死亡蛋白1配體2(PDL2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Arthritis Research & Therapy | Identification of definitive serum biomarkers associated with disease activity in primary Sj?gren's syndrome [Pubmed:27180164] |